The first cancers to be eradicated by CAR T cell therapy were CD19+ malignancies, and, in 2017, the US Food and Drug administration (FDA) approved CD19 CAR T cell therapy for treatment of B cell malignancies [31,32]. Here, CD19 is linked to cancer.